Addendum to clinical guideline 30 long-acting reversible contraception

The NICE surveillance programme reviewed the guideline on Long-acting reversible contraception (NICE clinical guideline 30) in 2011, and found changes to product licensing that affected the section of the guideline on progestogen-only subdermal implants. The full report can be found here: http://www...

Full description

Bibliographic Details
Corporate Author: National Institute for Health and Care Excellence (Great Britain)
Format: eBook
Language:English
Published: London National Institute for Health and Care Excellence (UK) September 2014, 2014
Series:Clinical guideline addendum
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02268nam a2200289 u 4500
001 EB001897046
003 EBX01000000000000001060051
005 00000000000000.0
007 tu|||||||||||||||||||||
008 200523 r ||| eng
245 0 0 |a Addendum to clinical guideline 30  |h Elektronische Ressource  |b long-acting reversible contraception  |c commissioned by the National Institute for Health and Care Excellence 
246 3 1 |a Long-acting reversible contraception 
246 3 1 |a Clinical Guideline 30.1, Long-acting reversible contraception 
260 |a London  |b National Institute for Health and Care Excellence (UK)  |c September 2014, 2014 
300 |a 1 PDF file (107 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Drug Implants 
653 |a Contraceptive Agents, Female 
653 |a Long-Acting Reversible Contraception 
710 2 |a National Institute for Health and Care Excellence (Great Britain) 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Clinical guideline addendum 
500 |a "This replaces chapter 7: Progestogen-only subdermal implants (POSDIs) in clinical guideline 30." 
856 4 0 |u http://www.ncbi.nlm.nih.gov/books/NBK550932  |3 Volltext 
082 0 |a 580 
520 |a The NICE surveillance programme reviewed the guideline on Long-acting reversible contraception (NICE clinical guideline 30) in 2011, and found changes to product licensing that affected the section of the guideline on progestogen-only subdermal implants. The full report can be found here: http://www.nice.org.uk/CG30/ New recommendations relating to progestogen-only subdermal implants have been made in this addendum. You are invited to comment on these new recommendations. Some recommendations can be made with more certainty than others. The wording used in the recommendations in this addendum denotes the certainty with which the recommendation is made (the strength of the recommendation). For all recommendations, NICE expects that there is discussion with the patient about the risks and benefits of the interventions, and their values and preferences. This discussion aims to help them to reach a fully informed decision (see also 'Patient-centred care')